Brief: Bionomics Announces The Completion Of Enrollment In Phase 2b ATTUNE Clinical Trial Of BNC210 In Patients With Post-Traumatic Stress Disorder
27/04/2023 11:08
April 27 (Reuters) - Bionomics Ltd BNO.AX :
* BIONOMICS ANNOUNCES THE COMPLETION OF ENROLLMENT IN PHASE
2B
ATTUNE CLINICAL TRIAL OF BNC210 IN PATIENTS WITH POST-TRAUMATIC
STRESS DISORDER (PTSD)
* BIONOMICS ANNOUNCES THE COMPLETION OF ENROLLMENT IN PHASE
2B
ATTUNE CLINICAL TRIAL OF BNC210 IN PATIENTS WITH POST-TRAUMATIC
STRESS DISORDER (PTSD)
* BIONOMICS LTD - TOPLINE RESULTS ARE EXPECTED IN Q3 OF 2023
Source text for Eikon: ID:nGNX1jhn6P
Further company coverage: BNO.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bionomics
See all newsBrief: Bionomics Announces Intention To Delist From The Australian Securities Exchange (ASX)
Brief: Bionomics Announces Its Intention To De-List From Australian Securities Exchange
Australia's Bionomics plunges to record low after co announces ASX delisting
Brief: Bionomics Ltd Seeks Trading Halt
Brief: Bionomics Says Alan Fisher Appointed Chair Of Board Of Directors